Philips Healthcare parent Royal Philips Electronics has signed a joint research agreement with Celsion of Columbia, MD, to develop a new cancer treatment, the company said.
Andover, MA-based Philips and Celsion will combine Philips' investigational MR-guided high-intensity focused ultrasound (HIFU) system with Celsion's leading drug candidate, ThermoDox (liposomal doxorubicin), to treat a broad range of cancers. The collaboration will use HIFU to position ThermoDox to create a mild hyperthermia that releases the drug directly into the tumor.
The two firms will test whether ThermoDox has the potential to eliminate cancer cells that might otherwise remain viable and could contribute to secondary tumors. HIFU would aid in releasing the concentrated drug within and around the margins of the heated area.
The trial would also examine whether using HIFU in the low-temperature activation mode in combination with ThermoDox has the potential to deliver high concentrations of chemotherapeutics to multiple sites at virtually any location in the body, according to Philips.
Related Reading
Philips introduces BrightView XCT, June 16, 2008
Philips, Skytron to build hybrid surgical rooms, June 12, 2008
Philips inks Premier deal, June 4, 2008
Philips to integrate STATdx with iSite, May 16, 2008
U.S. FDA warns Philips Medical over procedures, April 23, 2008
Copyright © 2008 AuntMinnie.com
